KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 6.37%.

  • Teva Pharmaceutical Industries' EBITDA Margin rose 70500.0% to 6.37% in Q4 2025 from the same period last year, while for Dec 2025 it was 12.49%, marking a year-over-year increase of 143200.0%. This contributed to the annual value of 12.5% for FY2025, which is 143300.0% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' EBITDA Margin is 6.37%, which was up 70500.0% from 19.69% recorded in Q3 2025.
  • Teva Pharmaceutical Industries' EBITDA Margin's 5-year high stood at 19.69% during Q3 2025, with a 5-year trough of 25.54% in Q2 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' median EBITDA Margin value was 4.14% (recorded in 2021), while the average stood at 1.88%.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' EBITDA Margin soared by 1251800bps in 2021, and later crashed by -404300bps in 2022.
  • Teva Pharmaceutical Industries' EBITDA Margin (Quarter) stood at 1.9% in 2021, then tumbled by -1372bps to 24.2% in 2022, then skyrocketed by 170bps to 16.96% in 2023, then tumbled by -104bps to 0.69% in 2024, then skyrocketed by 1029bps to 6.37% in 2025.
  • Its EBITDA Margin stands at 6.37% for Q4 2025, versus 19.69% for Q3 2025 and 10.9% for Q2 2025.